A Small Molecule That Blocks Mast Cell Reactions Triggered by Substance P and Other Peptides

Researchers tested C9 in multiple cell systems: RBL-2H3 cells engineered to express human MRGPRX2, LAD2 mast cell line, human skin-derived mast cells, and mouse peritoneal mast cells. They measured degranulation using β-hexosaminidase release, CD63 and CD107a surface expression. They also assessed β-arrestin recruitment and receptor internalization. The inactive analog C7 served as a negative control, and various agonists (substance P, PAMP-12, rocuronium, C3a, IgE crosslinking) were used to test selectivity.

Many drug hypersensitivity reactions and chronic skin conditions like urticaria, itch, and neurogenic inflammation are driven by mast cell activation through MRGPRX2 — not through traditional IgE allergies. Current treatments like antihistamines and steroids are broad and often inadequate. A selective MRGPRX2 blocker like C9 could offer a targeted approach to these conditions while leaving the immune system's IgE-based defenses intact.

MRGPRX2 has emerged as a major player in non-IgE allergic reactions, including dangerous hypersensitivity to drugs used during anesthesia. The neuropeptide substance P, which drives neurogenic inflammation and chronic itch, activates mast cells through this same receptor. This study establishes C9 as a proof-of-concept for a new drug class — selective MRGPRX2 inverse agonists — that could treat a range of conditions from drug allergies to atopic dermatitis to chronic pain.

All experiments were conducted in cell lines, engineered cells, or isolated mouse mast cells — no in vivo animal studies or human trials were performed. C9 did not block the mouse ortholog MrgprB2, which limits the ability to test it in mouse disease models. The long-term effects, bioavailability, and safety profile of C9 are unknown. Translation from cell culture to clinical therapy remains a significant gap.